Pneumococcal Vaccines Market - 2026-2033
Pneumococcal Vaccines Market reached US$ 8.73 billion in 2025 and is expected to reach US$ 13.02 billion by 2033, growing with a CAGR of 5.20% during the forecast period 2026-2033.
The Pneumococcal Vaccines Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Pneumococcal Vaccines Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Type
Both primary and secondary data sources have been used in the global Pneumococcal Vaccines Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Pneumococcal Vaccines Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Pneumococcal Vaccines Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Type
- Pneumococcal Conjugate Vaccine (PCV) *
- PCV 10
- PCV 13
- PCV 15
- PCV 20
- PCV 21
- Pneumococcal Polysaccharide Vaccine (PPV)
- Next Generation Pneumococcal Vaccines
- Intramuscular*
- Subcutaneous
- Infants (< 1 Year) *
- Children (1-12 Years)
- Adolescence (13-19 Years)
- Adults (20-60 Years)
- Geriatrics (Above 60 Years)
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Pneumococcal Vaccines Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Route of Administration
3.3. Snippet by Patient Type
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Awareness Campaigns and Programs Worldwide
4.1.1.2. Rising Innovations and Product Approvals
4.1.2. Restraints
4.1.2.1. Discrepancies in the Supply Chain
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. BY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Pneumococcal Conjugate Vaccine (PCV) *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. PCV
6.2.4. PCV
6.2.5. PCV
6.2.6. PCV
6.2.7. PCV
6.3. Pneumococcal Polysaccharide Vaccine (PPV)
6.4. Next Generation Pneumococcal Vaccines
7. BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Intramuscular*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Subcutaneous
8. BY PATIENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
8.1.2. Market Attractiveness Index, By Patient Type
8.2. Infants (< 1 Year) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Children (1-12 Years)
8.4. Adolescence (13-19 Years)
8.5. Adults (20-60 Years)
8.6. Geriatrics (Above 60 Years)
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10. COMPETITIVE LANDSCAPE
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. COMPANY PROFILES
11.1. Pfizer Inc. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Merck & Co., Inc.
11.3. Serum Institute of India Pvt. Ltd.
11.4. Walvax Biotechnology Co., Ltd.
11.5. SINOVAC
11.6. Beijing Minhai Biological Technology Co., Ltd.
11.7. SK bioscience.
11.8. Sanofi
11.9. Biological E Limited.
11.10. CanSinoBIO
11.11. Panacea Biotec
11.12. GSK plc.
11.13. Inventprise (*LIST NOT EXHAUSTIVE)
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Route of Administration
3.3. Snippet by Patient Type
3.4. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Awareness Campaigns and Programs Worldwide
4.1.1.2. Rising Innovations and Product Approvals
4.1.2. Restraints
4.1.2.1. Discrepancies in the Supply Chain
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. BY TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Pneumococcal Conjugate Vaccine (PCV) *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. PCV
6.2.4. PCV
6.2.5. PCV
6.2.6. PCV
6.2.7. PCV
6.3. Pneumococcal Polysaccharide Vaccine (PPV)
6.4. Next Generation Pneumococcal Vaccines
7. BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Intramuscular*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Subcutaneous
8. BY PATIENT TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
8.1.2. Market Attractiveness Index, By Patient Type
8.2. Infants (< 1 Year) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Children (1-12 Years)
8.4. Adolescence (13-19 Years)
8.5. Adults (20-60 Years)
8.6. Geriatrics (Above 60 Years)
9. BY REGION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
10. COMPETITIVE LANDSCAPE
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. COMPANY PROFILES
11.1. Pfizer Inc. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Merck & Co., Inc.
11.3. Serum Institute of India Pvt. Ltd.
11.4. Walvax Biotechnology Co., Ltd.
11.5. SINOVAC
11.6. Beijing Minhai Biological Technology Co., Ltd.
11.7. SK bioscience.
11.8. Sanofi
11.9. Biological E Limited.
11.10. CanSinoBIO
11.11. Panacea Biotec
11.12. GSK plc.
11.13. Inventprise (*LIST NOT EXHAUSTIVE)
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
